For research access and to learn how you can work with Alembic Global Advisors please email Stephen Matthews, stephen.matthews@alembicglobal.com.
Key Points Higher PE prices and self-help could drive significant EBITDA upside Global ethylene capacity closures could accelerate the next upcycle We rate DOW shares Overweight with a USD40 per share 12-month target...
Key Points We’re updating our forecast for NOC post the firm’s 3Q results last week, and we’re reiterating our Overweight rating on the shares. We’re also maintaining our target price at USD699...
Key Points We’re raising our top- and bottom-line forecast for RTX post the firm’s 3Q results earlier this week, and we’re reiterating our Overweight rating on the shares. That said, we’re reducing...
Key Points Q3’26 EPS and EBITDA beat on pricing strength; Q4’26 guidance above consensus Near-term commentary and guidance mixed We rate Dow Inc. shares Overweight with a 12-month target price of USD40 per...
Key Points Earnings revisions, not leverage alone, drive equity performance Debt maturities and recovery hurdles differentiate balance-sheet risk OLN/HUN offer cyclical leverage; CE/TROX offer self-help potential Summary Chemical equities have exhibited significant performance dispersion in...